SciSparc (NASDAQ:SPRC) Raised to “Sell” at Wall Street Zen

SciSparc (NASDAQ:SPRC) was upgraded by equities research analysts at Wall Street Zen to a “sell” rating in a report released on Saturday.

SciSparc Stock Performance

Shares of SPRC opened at $1.81 on Friday. The company’s 50 day simple moving average is $5.13 and its 200-day simple moving average is $6.09. SciSparc has a 12-month low of $1.75 and a 12-month high of $37.59.

About SciSparc

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.